Intranasal AdipoRon mitigates motor and cognitive deficits in hemiparkinsonian rats through neuroprotective mechanisms against oxidative stress and synaptic dysfunction DOI

Soraya Alimohammadi,

Gisou Mohaddes, ‬Rana Keyhanmanesh

et al.

Neuropharmacology, Journal Year: 2024, Volume and Issue: 262, P. 110180 - 110180

Published: Oct. 10, 2024

Language: Английский

AdipoRon’s Impact on Alzheimer’s Disease—A Systematic Review and Meta-Analysis DOI Open Access
Sandra Maria Barbalho, Lucas Fornari Laurindo,

Bárbara de Oliveira Zanuso

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(2), P. 484 - 484

Published: Jan. 8, 2025

Alzheimer's disease (AD) remains a leading cause of cognitive decline and mortality worldwide, characterized by neurodegeneration, synaptic deficiencies, neuroinflammation. Despite advancements in early detection, diagnosis, treatment, AD presents substantial challenges due to its complex pathology, heterogeneity, the limited efficacy current therapies. Consequently, there is pressing need for novel therapeutic agents target multifaceted aspects enhance treatments, minimize adverse effects. AdipoRon, an adiponectin receptor agonist, has garnered interest potential neuroprotective effects, including reducing neuroinflammation, improving mitochondrial function, mitigating tau hyperphosphorylation. This review aimed evaluate effects AdipoRon-based replacement therapy against AD, using comprehensive approach grounded PICO framework-Population, Intervention, Comparison, Outcomes. A total six studies were reviewed, vitro vivo investigations examining AdipoRon's impact on various models. These involved different cell lines transgenic mouse models, assessing outcomes such as phosphorylation, relevant molecular pathways. By synthesizing data from these studies, our thoroughly explains mechanisms action, agent AD. analysis aims highlight state knowledge, identify gaps research, suggest directions future clinical applications.

Language: Английский

Citations

2
MicroRNAs in Parkinson’s disease: From pathogenesis to diagnostics and therapeutic strategies DOI

Dongying Zheng,

Jibing Chween

Neuroscience, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 1, 2025

Language: Английский

Citations

2
rTMS ameliorates CUMS-induced anxiety-depression-like behaviour and cognitive dysfunction in rats by modulating the COX-2/PGE2 signalling pathway DOI

Yanjiao Pei,

Huanhuan Liu,

Jiqing Lang

et al.

Journal of Psychiatric Research, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
Intranasal AdipoRon mitigates motor and cognitive deficits in hemiparkinsonian rats through neuroprotective mechanisms against oxidative stress and synaptic dysfunction DOI

Soraya Alimohammadi,

Gisou Mohaddes, ‬Rana Keyhanmanesh

et al.

Neuropharmacology, Journal Year: 2024, Volume and Issue: 262, P. 110180 - 110180

Published: Oct. 10, 2024

Language: Английский

Citations

1